Inlyta 5 mg (Axitinib TABLET) 5 MG

INLYTA 5 MG tablets are an oral medication used to manage certain types of cancer. This pharmaceutical, manufactured by Pfizer Canada ULC, is designed to support treatment protocols for advanced conditions.

Strength

5 MG

Pack Size

28/56/60

Manufacturer / TM Owner

PFIZER CANADA ULC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

INLYTA 5 MG tablets are typically used in the treatment of advanced renal cell carcinoma, a type of kidney cancer. This medication is often prescribed for patients who have experienced disease progression after prior therapy. The primary use of INLYTA is to help manage and slow the progression of cancer in these specific cases.

Side Effects

Common effects of INLYTA 5 MG tablets may include fatigue, diarrhea, and high blood pressure. Some users might also experience decreased appetite, nausea, and vomiting. These effects can vary from person to person, and it's important to monitor any changes in health while using this medication.

Precautions & Warnings

INLYTA 5 MG tablets should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should be aware of potential side effects and report any severe or persistent symptoms to their healthcare provider.

Avoid Interactions

INLYTA 5 MG tablets may interact with certain medications, including those metabolized by the liver's CYP3A4 enzyme. It is advisable to consult a healthcare professional before combining INLYTA with other medications, especially those known to affect liver function. Additionally, grapefruit and grapefruit juice should be avoided as they can impact the effectiveness of this medication.

Frequently Asked Questions

INLYTA is primarily used in the treatment of advanced renal cell carcinoma, a type of kidney cancer, particularly in patients who have experienced disease progression after prior therapy.

INLYTA 5 MG tablets are taken orally, typically as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions.

Common side effects of INLYTA may include fatigue, diarrhea, high blood pressure, decreased appetite, nausea, and vomiting.

INLYTA may interact with certain medications, especially those metabolized by the liver's CYP3A4 enzyme. Consult a healthcare professional before combining INLYTA with other medications.

Patients should follow the prescribed dosage and administration instructions, monitor for side effects, and report any severe or persistent symptoms to their healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.